1Park, M, Braun, T & Carrin, G (2007) Technical Briefs for Policymakers. WHO Department of Health Systems Financing No. 2. Geneva: World Health Organization.
2Ginsburg, PB (2004) Controlling health care costs. N Engl J Med 351, 1591–1593.
3World Health Organization & European Observatory on Health Systems and Policies Series (2005) Purchasing to Improve Health Systems Performance [, editors]. Milton Keynes: Open University Press.
4Drummond, MF, Dubois, D, Garattini, L, et al. (1999) Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 2, 323–332.
5Lenoir-Wijnkoop, I, Dapoigny, M, Dubois, D, et al. (2011) Nutrition economics: characterising the economic and health impact of nutrition. Br J Nutr 105, 157–166.
6Fayers, P & Bottomley, A (2002) Quality of life research within the EORTC – the EORTC QLQ-C30. Eur J Cancer 38, S125–S133.
7Leidy, NK, Revicki, DA & Genesté, B (1999) Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 2, 113–127.
9Drummond, M, Brixner, D, Gold, M, et al. (2009) Toward a consensus on the QALY. Value Health 12, S31–S35.
10Cambridge, Harvard School of Public Health (1996) The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020 [, editors]. Cambridge, MA: Harvard School of Public Health.
11Torrance, GW, Furlong, W, Feeny, D, et al. (1995) Multiattribute preference functions. Health Utilities Index. Pharmacoeconomics 7, 503–520.
12Arnesen, T & Trommald, M (2005) Are QALYs based on time trade-off comparable? A systematic review of TTO methodologies. Health Econ 14, 39–53.
13The EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208.
14Richardson, J, Iezzi, A, Sihna, K, et al. (2009) .
15World Bank & World Development Report (1993) Investing in Health. New York: Oxford University Press.
16Soares, MO (2012) Is the QALY blind, deaf and dumb to equity? NICE's considerations over equity. Br Med Bull 101, 17–31.
17Muldoon, MF, Barger, SD, Flory, JD, et al. (1998) What are quality of life measurements measuring? Br Med J 316, 542–545.
18Slevin, ML, Plant, H, Lynch, D, et al. (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57, 109–112.
20Fried, TR, Tinetti, ME, Towle, V, et al. (2011) Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med 171, 923–928.
21Fidler, C, Christensen, TE & Gillard, S (2011) Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 14, 646–655.
22Nnoaham, KE, Sacks, G, Rayner, M, et al. (2009) Modelling income group differences in the health and economic impacts of targeted food taxes and subsidies. Int J Epidemiol 38, 1324–1333.
23Duffey, KJ, Gordon-Larsen, P, Shikany, JM, et al. (2010) Food price and diet and health outcomes: 20 years of The CARDIA Study. Arch Intern Med 5, 420–426.
25Ståhl, T (2010) Is health recognised in the EU's policy process? An analysis of the European Commission's impact assessments. Eur J Public Health 2, 176–181.
26Ubel, PA, Baron, J, Nash, B, et al. (2002) Are preferences for equity over efficiency in health care allocation “all or nothing”? Med Care 38, 366–373.
28Graves, N (2006) Cost-effectiveness analyses and modelling the lifetime costs and benefits of health-behaviour interventions. Chronic Illness 2, 97–107.
29Lenoir-Wijnkoop, I, van Aalderen, WM, Boehm, G, et al. (2012) Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands. Eur J Health Econ 13, 101–110.
30Lötters, FJB, Lenoir-Wijnkoop, I, Fardellone, P, et al. (2012) Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporos Int .
31Lotan, Y, Buendia Jiménez, I, Lenoir-Wijnkoop, I, et al. (2012) Primary prevention of nephrolithiasis is cost-effective for a national health care system. Br J Urol (epublication ahead of print version 11 June 2012).
32Puska, P, Nissinen, A & Tuomilehto, J (1985) The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia project. Ann Rev Public Health 6, 147–193.
33Puska, P (2009) Fat and heart disease: yes we can make a change – the case of North Karelia (Finland). Ann Nutr Metab 54, S33–S38.
34Puska, P & Ståhl, T (2010) Health in all policies – the Finnish initiative: background, principles, and current issues. Annu Rev Public Health 31, 315–328.
35Sesé, MA, Jiménez-Pavón, D, Gilbert, CC, et al. (2012) Eating behaviour, insulin resistance and cluster of metabolic risk factors in European adolescents. The HELENA Study. Appetite 59, 140–147.
37Duffey, KJ, Steffen, LM, Van Horn, L, et al. (2012) Dietary patterns matter: diet beverages and cardiometabolic risks in the longitudinal Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Clin Nutr 95, 909–915.
38Buckland, G, Agudo, A, Luja'n, L, et al. (2010) Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. Am J Clin Nutr 91, 381–390.
39Blumfield, M, Hure, A, MacDonald-Wicks, L, et al. (2011) Disparities exist between national food group recommendations and the dietary intakes of women. BMC Women's Health 11, 37.
40Upshur, REG (2003) Are all evidence-based practices alike? Problems in the ranking of evidence. CMAJ 169, 672–673.
41Tonelli, MR (2001) The limits of evidence-based medicine. Resp Care 46, 1435–1440.
42Rothwell, PM (2005) External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 365, 82–93.
43Ioannidis, JPA (2008) Some main problems eroding the credibility and relevance of randomized trials. Bull NYU Hosp Joint Dis 66, 135–139.
44Guyatt, GH, Oxman, AD, Kunz, R, et al. (2008) Rating quality of evidence and strength of recommendations: what is “quality of evidence” and why is it important to clinicians? BMJ 336, 995–998.
46Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group (2004) Grading quality of evidence and strength of recommendations. BMJ 328, 1490.
47Ibargoyen-Roteta, N, Gutierrez-Ibarluzea, I, Rico-Iturrioz, R, et al. (2010) The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implement Sci 16, 48.
48Nathan, DM, Buse, JB, Davidson, MB, et al. (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29, 1963–1972.
49American Diabetes Association (2008) Clinical practice recommendations. Standards of medical care in diabetes – 2008. Diabetes Care 31, Suppl. 1, S12–S54.
50Agence Française de Sécurité Sanitaire des Produits de Santé (2006) Traitement médicamenteux de l'ostéoporose post-ménopausique. Recommendations (Drug Treatment of Postmenopausal Osteoporosis. Recommendations). Saint-Denis: Agence Française de Sécurité Sanitaire des Produits de Santé.
51Nuijten, M, Renkens, M, Kogels, E, et al. (2011) The decision making process of payers: a pilot survey in The Netherlands. ISPOR Connections 8–9.
52Plotnikoff, GA (2003) Food as medicine – cost-effective health care? Minnesota Med 86, 41–45.
53McCarron, DA & Heaney, RP (2004) Estimated healthcare savings associated with adequate dairy food intake. Am J Hypertens 17, 88–97.
54Dalziel, K & Segal, L (2007) Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions. Health Prom Int 22, 271–283.
55Doidge, JC, Gospodarevskaya, E & Segal, L (2011) .